Paper of the Month - April, 2010

0 rating

Results of a Phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.



READER POLL

L&L poll 2
What do you consider to be the most exciting advances in therapeutics research in myeloid leukemia at present?






Powered by NetPolls

SUBMIT AN ARTICLE